Below are current clinical trials.11 studies in Type 1 diabetes
(open studies only).
Filter this list of studies by location, status and more.
OBJECTIVE— The Diabetes Control and Complications Trial (DCCT) demonstrated the powerful impact of glycemic control on the early manifestations of microvascular complications.
Contemporary prospective data on the evolution of macrovascular and late micro vascular complications of type 1 diabetes are limited. The Epidemiology of Diabetes Interventions and Complications (EDIC) study is a multicenter, longitudinal, observational study designed to use the well-characterized DCCT cohort of 1,400 patients to determine the long-term effects of prior separation of glycemic levels on micro- and macrovascular outcomes. EDIC is in its 13th year of followup. The study is expecting to last until 2016.
RESEARCH DESIGN AND METHODS— Using a standardized annual history and physical examination, 28 EDIC clinical centers that were DCCT clinics will follow the EDIC cohort for 10 years. Annual evaluation also includes resting electro c a rdiogram, Doppler ultrasound measurements of ankle/arm blood pressure, and screening for nephropathy. At regular intervals, a timed 4-h urine is collected, lipid pro files are obtained, and stereoscopic fundus photographs are taken. In addition, dual B-mode Doppler ultrasound scans of the common and internal carotid arteries will be perf o rmed at years 1 and 6 and at study end.
This research study is being done to develop educational materials that will help patients and clinicians talk about diabetes treatment and management options.
This purpose of this study is to determine if activation of a person's immune system in the small intestine could be a contributing cause of Type 1 Diabetes.
Although vitreous hemorrhage (VH) from proliferative diabetic retinopathy (PDR) can cause acute and dramatic vision loss for patients with diabetes, there is no current, evidence-based clinical guidance as to what treatment method is most likely to provide the best visual outcomes once intervention is desired. Intravitreous anti-vascular endothelial growth factor (anti-VEGF) therapy alone or vitrectomy combined with intraoperative PRP each provide the opportunity to stabilize or regress retinal neovascularization. However, clinical trials are lacking to elucidate the relative time frame of visual recovery or final visual outcome in prompt vitrectomy compared with initial anti-VEGF treatment. The Diabetic Retinopathy Clinical Research Network Protocol N demonstrated short-term trends consistent with a possible beneficial effect of anti-VEGF treatment in eyes with VH from PDR, including greater visual acuity improvement and reduced rates of recurrent VH as compared with saline injection. It is possible that a study with a longer duration of follow-up with structured anti-VEGF retreatment would demonstrate even greater effectiveness of anti-VEGF for VH to avoid vitrectomy and its attendant adverse events while also improving visual acuity. On the other hand, advances in surgical techniques leading to faster operative times, quicker patient recovery, and reduced complication rates may make prompt vitrectomy a more attractive alternative since it results in the immediate ability to clear hemorrhage and to perform PRP if desired, often as part of one procedure. This proposed study will evaluate the safety and efficacy of two treatment approaches for eyes with VH from PDR: prompt vitrectomy + PRP and intravitreous aflibercept injections.
The purpose of this study is to develop a better blood test to diagnose early kidney injury in type 1 diabetes.
The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and are on the waiting list for either a pancreas alone or a pancreas and kidney transplant.
The purpose of this study is to evaluate the effects of improving glycemic control, and/or reducing glycemic variability on gastric emptying, intestinal barrier function, autonomic nerve functions, and epigenetic changes in subjects with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) who are switched to intensive insulin therapy as part of clinical practice.
The purpose of this study is to evaluate glucose variability in patients with type 1 diabetes (T1D) and insulin antibodies, to evaluate the clinical significance of insulin antibodies, and to establish an in vitro assay that would detect antibodies to insulin and insulin analogs.
This study is being done to determine the roles that several molecules play in the repair of injured cells that line your blood vessels.
Hypothesis: Increased contact with the diabetes care team throughout pregnancy will lead to improved glucose control during pregnancy.
Aug. 07, 2017
- Standards of medical care in diabetes — 2017: Summary of revisions. Diabetes Care. 2017;40(suppl):S5.
- Papadakis MA, et al., eds. Diabetes mellitus & hypoglycemia. In: Current Medical Diagnosis & Treatment 2017. 56th ed. New York, N.Y.: McGraw-Hill Education; 2017. http://accessmedicine.mhmedical.com. Accessed April 19, 2017.
- What is diabetes? National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes. Accessed April 19, 2017.
- Levitsky LL, et al. Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents. https://www.uptodate.com/home. Accessed April 19, 2017.
- Diabetes mellitus (DM). Merck Manual Professional Version. http://www.merckmanuals.com/professional/endocrine_and_metabolic_disorders/diabetes_mellitus_and_disorders_of_carbohydrate_metabolism/diabetes_mellitus_dm.html. Accessed April 19, 2017.
- AskMayoExpert. Type 1 diabetes mellitus. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Robertson RP, et al. Pancreas and islet transplantation in diabetes mellitus. https://www.uptodate.com/home. Accessed April 21, 2017.
- Levitsky LL, et al. Special situations in children and adolescents with type 1 diabetes mellitus. https://www.uptodate.com/home. Accessed April 19, 2017.
- Hyperglycemia (High blood glucose). American Diabetes Association. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html. Accessed April 19, 2017.
- DKA (ketoacidosis) and ketones. American Diabetes Association. http://www.diabetes.org/living-with-diabetes/complications/ketoacidosis-dka.html. Accessed April 19, 2017.
- Prediabetes & insulin resistance. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance. Accessed April 19, 2017.
- About insulin and high blood glucose. American Diabetes Association. http://www.diabetes.org/are-you-at-risk/lower-your-risk/highbg.html. Accessed April 19, 2017.
- McCulloch DK, et al. Glycemic control and vascular complications in type 1 diabetes. https://www.uptodate.com/home. Accessed April 20, 2017.
- Diabetes and oral health problems. American Diabetes Association. http://www.diabetes.org/living-with-diabetes/treatment-and-care/oral-health-and-hygiene/diabetes-and-oral-health.html. Accessed April 20, 2017.
- Drug treatment of diabetes mellitus. Merck Manual Professional Version. http://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-disorders-of-carbohydrate-metabolism/drug-treatment-of-diabetes-mellitus. Accessed April 21, 2017.
- McCulloch DK, et al. Management of blood glucose in adults with type 1 diabetes mellitus. https://www.uptodate.com/home. Accessed April 21, 2017.
- FDA proves first automated insulin delivery device for type 1 diabetes. U.S. Food and Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm. Accessed April 21, 2017.
- Forlena GP. Insulin infusion sets and continuous glucose monitoring sensors: Where the artificial pancreas meets the patient. Diabetes Technology and Therapeutics. 2017;19:206.
- Hypoglycemia. American Diabetes Association. http://professional.diabetes.org/pel/hypoglycemia-english. Accessed April 21, 2017.
- Questions & answers about diabetes in the workplace and the Americans with disabilities act. U.S. Equal Opportunity Employment Commission. https://www.eeoc.gov/laws/types/diabetes.cfm. Accessed April 21, 2017.
- Castro MR (expert opinion). Mayo Clinic, Rochester, Minn. May 9, 2017.